Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Theoretical and Numerical Investigation of the Consistency of Model Comparisons in Pharmacometrics.

The AAPS journal·2026
Same author

A linear pathway for inositol pyrophosphate metabolism revealed by 18O labeling and model reduction.

PLoS computational biology·2025
Same author

Pools of Independently Cycling Inositol Phosphates Revealed by Pulse Labeling with <sup>18</sup>O-Water.

Journal of the American Chemical Society·2025
Same author

Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEM.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Likelihood-ratio test statistic for the finite-sample case in nonlinear ordinary differential equation models.

PLoS computational biology·2023

Related Experiment Video

Updated: Nov 10, 2025

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

4.4K

Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40.

Jacques Hermes1,2,3, Bernhard Steiert1

  • 1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Translational Vision Science & Technology
|September 2, 2025
PubMed
Summary

Integrating home optical coherence tomography (OCT) with pharmacokinetic/pharmacodynamic (PK/PD) modeling significantly reduces clinical trial sample sizes for retinal diseases. This approach enhances trial efficiency and patient convenience while maintaining statistical power.

More Related Videos

In vivo Structural Assessments of Ocular Disease in Rodent Models using Optical Coherence Tomography
07:44

In vivo Structural Assessments of Ocular Disease in Rodent Models using Optical Coherence Tomography

Published on: July 24, 2020

3.0K
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.4K

Related Experiment Videos

Last Updated: Nov 10, 2025

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

4.4K
In vivo Structural Assessments of Ocular Disease in Rodent Models using Optical Coherence Tomography
07:44

In vivo Structural Assessments of Ocular Disease in Rodent Models using Optical Coherence Tomography

Published on: July 24, 2020

3.0K
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.4K

Area of Science:

  • Ophthalmology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Clinical trials for retinal diseases face challenges including patient variability and long follow-up periods.
  • Detecting treatment effects is often hindered by high variability in endpoints.

Purpose of the Study:

  • To investigate if home optical coherence tomography (OCT) monitoring combined with pharmacokinetic/pharmacodynamic (PK/PD) modeling can reduce sample size requirements in early-stage retinal disease clinical trials.
  • To assess the efficiency of integrating novel monitoring technologies with established modeling techniques.

Main Methods:

  • Developed a population PK/PD model utilizing longitudinal central subfield thickness data from home OCT monitoring.
  • Employed Monte Carlo simulations and bootstrapping to assess sample size needs under various monitoring strategies.
  • Simulated an effect size of approximately 50-µm central subfield thickness reduction.

Main Results:

  • Home OCT monitoring required 33-35 patients per arm, compared to 41-54 patients for traditional biweekly in-clinic monitoring.
  • This represents a 20% to 40% reduction in sample size needed to detect the simulated treatment effect.
  • The PK/PD model effectively utilized home-based data to inform trial parameters.

Conclusions:

  • Home OCT monitoring integrated with PK/PD modeling offers a more efficient approach to clinical trials for retinal diseases.
  • This strategy can improve trial efficiency, enhance patient convenience, and expedite the development of new retinal therapies.
  • Reduced sample size requirements maintain statistical power, potentially improving patient access to novel treatments.